Clinical Trial Update: Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants [Phase 1]

View source ↗

Summary

Novartis is conducting a Phase 1 study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of NIO752 in participants with early Alzheim…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• NIO752

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimer Disease, Mild Cognitive Impairment | Phase 1 | Status: RECRUITING